Cerence Inc

CRNC remains in a Stage 2 advancing regime undergoing a corrective reset. The medium-term bias stays bullish on higher-highs/higher-lows intact above the rising 50 DMA, while short-term price is being rejected by the flattened 9/21 EMA zone. Execution is deferred (Stalk), with focus on pullbacks into 50 DMA support or upon reclaim and acceptance of the 9/21 EMAs.

• ↑Q3 revenue of $69.6M (+12% YoY) fuels growth narrative.
• ↑GAAP net income returned to $1.5M and adjusted EBITDA rose 50% to $13.5M.
• ↓Negative earnings yield and profitability scores signal weak returns.